We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




New Ventless Device Addresses Significant Challenge of Blood Culture Contamination

By LabMedica International staff writers
Posted on 17 Feb 2023
Print article
Image: Kurin Jet marks a significant technological advance over the company’s own market-leading Kurin Lock (Photo courtesy of Kurin)
Image: Kurin Jet marks a significant technological advance over the company’s own market-leading Kurin Lock (Photo courtesy of Kurin)

Determining whether a bloodstream infection is present in patients is vital for their wellbeing as well as for the financial health of hospitals. The gold standard for identifying bacteremia is a blood culture test with millions of such tests being conducted annually to inform patient care decisions. However, contaminated blood cultures create a significant problem, as approximately one-third of all positive results are wrong, resulting in unnecessary antibiotics being administered to patients, longer hospital stays and a negative impact on larger community health issues, like antimicrobial resistance and life-threatening C. diff. infections. Now, a new ventless device with its unique design, speed, and ease of use can help hospitals address the significant challenge of blood culture contamination.

Kurin, Inc. (San Diego, CA, USA) has announced the limited commercial release of Kurin Jet, which is a significant technological advance over the company’s own market-leading Kurin Lock. Kurin’s revolutionary approach to the problem of contaminated blood culture is based on simple, intuitive designs that does not require any additional user steps. Similar to the Kurin Lock, the Kurin Jet also passively sidelines potential contaminants during blood culture collection. Both Kurin Lock and Kurin Jet offer a better and more sustainable approach than active, conventional mechanical diversion.

“We are excited to announce the introduction of Kurin Jet, a fundamentally different product that provides a new level of performance in addressing the blood culture contamination market,” said Bob Rogers, CEO of Kurin, Inc. “Although our current Kurin Lock is the market leader because of its small size and passive, user-friendly design, we have leapfrogged that technology and created a much faster device with a greater level of control for clinicians. Kurin Jet can be used with direct to media, syringe draw, direct venipuncture and PIV applications.”

“Kurin Jet helps hospitals address the significant challenge of blood culture contamination with its unique design, speed, and ease of use. Based on its performance and feedback from those who have used Jet, we will limit the initial release, as demand will exceed initial production volumes. Full release will occur later this year,” added Rogers.

Related Links:
Kurin, Inc.

Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Vaginitis Test
Allplex Vaginitis Screening Assay
New
Centromere B Assay
Centromere B Test

Print article

Channels

Molecular Diagnostics

view channel
Image: The experimental blood test accurately indicates severity and predicts potential recovery from spinal cord injury (Photo courtesy of 123RF)

Blood Test Identifies Multiple Biomarkers for Rapid Diagnosis of Spinal Cord Injury

The National Institutes of Health estimates that 18,000 individuals in the United States sustain spinal cord injuries (SCIs) annually, resulting in a staggering financial burden of over USD 9.... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Industry

view channel
Image: Tumor-associated macrophages visualized using the Multiomic LS Assay (Photo courtesy of ACD)

Leica Biosystems and Bio-Techne Expand Spatial Multiomic Collaboration

Bio-Techne Corporation (Minneapolis, MN, USA) has expanded the longstanding partnership between its spatial biology brand, Advanced Cell Diagnostics (ACD, Newark, CA, USA), and Leica Biosystems (Nussloch,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.